Brief: Oncopeptides Q3 Operating Profit SEK -61.251 Million
07/11/2024 07:00
Nov 07 (Reuters) - Oncopeptides Q3 adjusted free cash flow SEK -130.484 million. * Q3 net income SEK -60.233 million * Q3 sales SEK 8.507 million * Q3 adjusted EPS SEK -1.16
Recent news on Oncopeptides AB
See all newsSweden's Oncopeptides Q3 net sales rise on Pepaxti demand
Brief: Oncopeptides Q3 Operating Profit SEK -36.47 Million
Brief: Oncopeptides Completes Directed Share Issue Of SEK 100 Mln
Brief: Oncopeptides Confirms Blood-Brain-Barrier Penetration In Glioblastoma Study
Swedish biotech Oncopeptides' Q2 net sales rise on strong demand in Italy